Merck KGaA (OTCMKTS:MKKGY – Get Free Report) has been assigned an average rating of “Hold” from the six analysts that are currently covering the firm, Marketbeat Ratings reports. Six analysts have rated the stock with a hold recommendation.
Several research analysts have recently commented on MKKGY shares. Jefferies Financial Group began coverage on shares of Merck KGaA in a research note on Tuesday, May 26th. They set a “hold” rating on the stock. UBS Group lowered shares of Merck KGaA from a “strong-buy” rating to a “hold” rating in a research note on Thursday, August 20th. HSBC upgraded shares of Merck KGaA to a “hold” rating in a report on Monday, July 6th. Finally, Zacks Research downgraded shares of Merck KGaA from a “strong-buy” rating to a “hold” rating in a research report on Thursday, August 20th.
Read Our Latest Analysis on MKKGY
Merck KGaA Price Performance
About Merck KGaA
Merck KGaA, Darmstadt, Germany, commonly referred to as Merck Group, is a multinational science and technology company with origins dating back to 1668. The company develops and manufactures products and technologies across healthcare, life science and electronics applications. It is distinct from the U.S. pharmaceutical company Merck & Co; Merck KGaA is a European group headquartered in Darmstadt and is publicly listed in Germany with an OTC American depositary receipt available under the symbol MKKGY.
Merck’s Healthcare business develops prescription medicines and related services focused on areas such as oncology, immunology, neurology (including therapies for multiple sclerosis) and fertility.
Recommended Stories
- Five stocks we like better than Merck KGaA
- The Path to $230 Billion: Broadcom Outlines the Next Phase of Its AI Growth Story
- NVIDIA’s Hugging Face Deal Raises a Bigger Question About Its AI Moat Now
- Dropping the Dough: Yum! Brands Strategically Trims the Fat
- These 3 Stock Charts Just Flashed the Dreaded Death Cross Pattern
Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.
